Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Health and economic impact of rotavirus vaccination in GAVI-eligible countries.

Kim SY, Sweet S, Slichter D, Goldie SJ.

BMC Public Health. 2010 May 14;10:253. doi: 10.1186/1471-2458-10-253.

2.

Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.

Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD.

J Infect Dis. 2009 Nov 1;200 Suppl 1:S16-27. doi: 10.1086/605026. Review.

PMID:
19817595
3.

Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries.

Plosker GL.

Paediatr Drugs. 2012 Dec 1;14(6):429-33. doi: 10.2165/11207500-000000000-00000. Review.

PMID:
23013458
4.

The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance.

Lee LA, Franzel L, Atwell J, Datta SD, Friberg IK, Goldie SJ, Reef SE, Schwalbe N, Simons E, Strebel PM, Sweet S, Suraratdecha C, Tam Y, Vynnycky E, Walker N, Walker DG, Hansen PM.

Vaccine. 2013 Apr 18;31 Suppl 2:B61-72. doi: 10.1016/j.vaccine.2012.11.035. Review.

PMID:
23598494
5.

Economic evaluations of rotavirus immunization for developing countries: a review of the literature.

Tu HA, Woerdenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ.

Expert Rev Vaccines. 2011 Jul;10(7):1037-51. doi: 10.1586/erv.11.65. Review.

PMID:
21806398
6.

Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Plosker GL.

Pharmacoeconomics. 2011 Nov;29(11):989-1009. doi: 10.2165/11207210-000000000-00000. Review.

PMID:
21988293
7.

Insights from global data for use of rotavirus vaccines in India.

Rao TS, Arora R, Khera A, Tate JE, Parashar U, Kang G; Indian Rotavirus Vaccine Working Group..

Vaccine. 2014 Aug 11;32 Suppl 1:A171-8. doi: 10.1016/j.vaccine.2014.03.029. Review.

8.

Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines.

Widdowson MA, Steele D, Vojdani J, Wecker J, Parashar U.

J Infect Dis. 2009 Nov 1;200 Suppl 1:S1-8. doi: 10.1086/605061. Review.

PMID:
19817589
9.

Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense?

Rheingans RD, Heylen J, Giaquinto C.

Pediatr Infect Dis J. 2006 Jan;25(1 Suppl):S48-55. Review.

PMID:
16397429
10.

Global economic evaluations of rotavirus vaccines: A systematic review.

Kotirum S, Vutipongsatorn N, Kongpakwattana K, Hutubessy R, Chaiyakunapruk N.

Vaccine. 2017 May 11. pii: S0264-410X(17)30543-1. doi: 10.1016/j.vaccine.2017.04.051. [Epub ahead of print] Review.

PMID:
28504193
11.

A critical literature review of health economic evaluations of rotavirus vaccination.

Aballéa S, Millier A, Quilici S, Caroll S, Petrou S, Toumi M.

Hum Vaccin Immunother. 2013 Jun;9(6):1272-88. doi: 10.4161/hv.24253. Epub 2013 Apr 9. Review.

12.

Do current cost-effectiveness analyses reflect the full value of childhood vaccination in Europe? A rotavirus case study.

Brüggenjürgen B, Lorrot M, Sheppard FR, Rémy V.

Hum Vaccin Immunother. 2014;10(8):2290-4. doi: 10.4161/hv.29090. Review.

13.

Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries.

Deogaonkar R, Hutubessy R, van der Putten I, Evers S, Jit M.

BMC Public Health. 2012 Oct 16;12:878. doi: 10.1186/1471-2458-12-878. Review.

14.

A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines.

Thiboonboon K, Santatiwongchai B, Chantarastapornchit V, Rattanavipapong W, Teerawattananon Y.

Appl Health Econ Health Policy. 2016 Dec;14(6):659-672. Review.

PMID:
27475634
15.

Delivering vaccines to the people who need them most.

Barocchi MA, Rappuoli R.

Philos Trans R Soc Lond B Biol Sci. 2015 Jun 19;370(1671). pii: 20140150. doi: 10.1098/rstb.2014.0150. Review.

16.

Gavi HPV Programs: Application to Implementation.

Hanson CM, Eckert L, Bloem P, Cernuschi T.

Vaccines (Basel). 2015 May 20;3(2):408-19. doi: 10.3390/vaccines3020408. Review.

17.

The contribution of vaccination to global health: past, present and future.

Greenwood B.

Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130433. doi: 10.1098/rstb.2013.0433. Print 2014. Review.

18.

Vaccination greatly reduces disease, disability, death and inequity worldwide.

Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, Lee BW, Lolekha S, Peltola H, Ruff TA, Santosham M, Schmitt HJ.

Bull World Health Organ. 2008 Feb;86(2):140-6. Review.

19.

Three decades of USAID investments in immunization through the child survival revolution.

Murray Trostle R, Shen AK.

Emerg Microbes Infect. 2014 Feb;3(2):e13. doi: 10.1038/emi.2014.13. Epub 2014 Feb 26. Review.

20.

Seizing market shaping opportunities for vaccine cold chain equipment.

Azimi T, Franzel L, Probst N.

Vaccine. 2017 Apr 19;35(17):2260-2264. doi: 10.1016/j.vaccine.2016.12.073. Review.

Supplemental Content

Support Center